Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Cited by (860)

Items 301–400 of 860

1. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
   Yuqing He, Mengyao Lu, Jing Che, Qian Chu, Peng Zhang, Yuan Chen · 2021 · Frontiers in Oncology
2. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors
   Yuki Yoshikawa, Michio Imamura, Masami Yamauchi, Clair Nelson Hayes, Hiroshi Aikata, Wataru Okamoto, Yoshihiro Miyata, Morihito Okada, Noboru Hattori, Kazuhiko Sugiyama et al. · 2022 · BMC Cancer
3. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors
   Grażyna Kamińska‐Winciorek, Bożena Cybulska-Stopa, Iwona A. Lugowska, Marek Ziobro, Piotr Lukasz Rutkowski · 2019 · Advances in Dermatology and Allergology
4. Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study
   L. Dousset, Alize Pacaud, Thomas Barnetche, Marie Kostine, Caroline Dutriaux, Anne Pham‐Ledard, Marie Beylot-Barry, Émilie Gerard, Sorilla Prey, Nicolas Andreu et al. · 2021 · JAAD International
5. Targeting CTLA ‐4, PD ‐L1 and IDO to modulate immune responses in vitiligo
   Reinhart Speeckaert, Nanja van Geel · 2016 · Experimental Dermatology
6. The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
   Marco Tucci, Anna Maria Passarelli, Annalisa Todisco, Francesco Mannavola, Luigia Stefania Stucci, Stella D’Oronzo, Michele Rossini, Marco Taurisano, Loreto Gesualdo, Franco Silvestris · 2019 · Therapeutic Advances in Medical Oncology
7. Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
   Ting Yan, Lun Yu, Jiwen Zhang, Yun Chen, Yilan Fu, Jingyi Tang, Dehua Liao · 2024 · Frontiers in Immunology
8. Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
   Ichiro Yamauchi, Daisuke Yabe · 2025 · European Thyroid Journal
9. Scleroderma‐like syndrome associated with nivolumab treatment in malignant melanoma
   Maria H. Cho, Yumi Nonomura, Yo Kaku, Shuichiro Nakabo, Yuichiro Endo, Atsushi Otsuka, Kenji Kabashima · 2018 · The Journal of Dermatology
10. Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses
    Monica Peravali, Cristiane Jeyce Gomes-Lima, Eshetu A Tefera, Mairead Baker, Mamta Sherchan, Saira Farid, Kenneth Dale Burman, Florina Constantinescu, Irina G. Veytsman · 2021 · World Journal of Clinical Oncology
11. Exploiting the obesity-associated immune microenvironment for cancer therapeutics
    Lysanne Desharnais, Logan A. Walsh, Daniela F. Quail · 2021 · Pharmacology & Therapeutics
12. Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study
    Sanna Iivanainen, Tuomo Alanko, Pia Vihinen, Teemu Konkola, Jussi Ekström, Henri Virtanen, Jussi Pekka Koivunen · 2020 · JMIR Formative Research
13. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review)
    Xianbin Kong, Peng Lü, Chuanxin Liu, Yuzhu Guo, Yuying Yang, Yingying Peng, Fangyuan Wang, Bo Zhang, Xiaoxin Dou, Haoyang Shi et al. · 2021 · Molecular Medicine Reports
14. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis
    Teppei Yamaguchi, Junichi Shimizu, Takaaki Hasegawa, Yoshitsugu Horio, Yoshitaka Inaba, Nobuhiro Hanai, Kei Muro, Toyoaki Hida · 2021 · BMC Cancer
15. Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D
    Peter S. Linsley, Sarah Alice Long · 2019 · Current Opinion in Endocrinology Diabetes and Obesity
16. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis
    Takayuki Ando, AKIRA UEDA, Kohei Ogawa, Iori Motoo, Shinya Kajiura, Takahiko Nakajima, Katsuhisa Hirano, Tomoyuki Okumura, Kenichiro Tsukada, Takuo Hara et al. · 2021 · In Vivo
17. Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study
    Saeka Egami, Hitoshi Kawazoe, Hironobu Hashimoto, Ryuji Uozumi, Toko Arami, Naomi Sakiyama, Yuichiro Ohe, Hideo Nakada, Tohru Aomori, Shinnosuke Ikemura et al. · 2021 · Frontiers in Oncology
18. Immune Checkpoint Blockade and Skin Toxicity Pathogenesis
    Barbara Ma, Niroshana Anandasabapathy · 2021 · Journal of Investigative Dermatology
19. Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
    Taketo Kawai, Satoru Taguchi, Tohru Nakagawa, Jun Kamei, Yu Nakamura, Daisuke Obinata, Kenya Yamaguchi, Tomoyuki Kaneko, Shigenori Kakutani, Mayuko Tokunaga et al. · 2022 · Journal for ImmunoTherapy of Cancer
20. Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
    Vasiliki A. Nikolaou, Antonios Tsimpidakis, Alexander Stratigos · 2023 · Cancers
21. Prognostic and predictive biomarkers in melanoma
    Nigel Gordon Maher, Ismael A. Vergara, Georgina Venetia Long, Richard A. Scolyer · 2023 · Pathology
22. Granuloma annulare associated with immune checkpoint inhibitors
    Jennifer Wu, Bernice Y. Kwong, Kathryn J. Martires, Kerri E. Rieger, Wen‐Hung Chung, Gopa Iyer, Mario E. Lacouture · 2017 · Journal of the European Academy of Dermatology and Venereology
23. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
    Nobuyuki Koyama, Osamu Iwase, E. Nakashima, Kosuke Kishida, Takahito Kondo, Yukako Watanabe, Hidenori Takahashi, Y. Umebayashi, Yasuo Ogawa, Hiroyuki Miura · 2018 · BMC Pulmonary Medicine
24. Nivolumab in melanoma
    Pol M. Specenier · 2016 · Expert Review of Anticancer Therapy
25. Immune‐related adverse events predict responses to PD ‐1 blockade immunotherapy in hepatocellular carcinoma
    Lianghe Lu, Kaili Xing, Wei Wei, Yihong Ling, Peng Li, Shaohua Li, Yan Wang, Dan Xie, Rong Guo, Muyan Cai · 2021 · International Journal of Cancer
26. Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
    Carmen Portenkirchner, Peter Kienle, Karoline Horisberger · 2021 · Pharmaceuticals
27. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management
    Shelley Ji Eun Hwang, Rachael M. Anforth, Giuliana Carlos, Pablo Fernández‐Peñas · 2016 · Actas Dermo-Sifiliográficas
28. Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors
    Filippo Gustavo Dall’Olio, Vincenzo Di Nunno, Francesco Massari · 2019 · Journal of Clinical Oncology
29. PD-1 is requisite for skin TRM cell formation and specification by TGFβ
    K. Sanjana P. Devi, Eric Wang, Abhinav Jaiswal, Piotr Konieczny, Tae‐Gyun Kim, Christopher J. Nirschl, Akanksha Verma, Yong Liu, Julia Milczanowski, Susan N. Christo et al. · 2025 · Nature Immunology
30. Efficacy and immune-related adverse event associations in avelumab-treated patients
    Karen L. Kelly, Juliane Manitz, Manish R. Patel, Sandra P. D’Angelo, Andrea Borghese Apolo, Arun Rajan, Vijay Kasturi, Isabell Speit, Marcis Bajars, John D. Warth et al. · 2020 · Journal for ImmunoTherapy of Cancer
31. Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors
    Nicholas Gulati, Douglas MacArthur Donnelly, Yingzhi Qian, Una Moran, Paul M. Johannet, Judy Zhong, Iman Osman · 2020 · Journal of Translational Medicine
32. Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients
    Georg Christian Lodde, Andrea Forschner, Jessica C. Hassel, Lena M. Wulfken, Friedegund Elke Meier, Peter Mohr, Katharina Charlotte Kähler, Bastian Schilling, Carmen Loquai, Carola Berking et al. · 2021 · Cancers
33. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
    Xin Bai, Xueyan Wang, Guozhen Ma, Jinen Song, Xiaowei Liu, Xi Lawrence Wu, Yujie Zhao, Xu Liu, Zhihui Liu, Wei Zhang et al. · 2021 · Frontiers in Immunology
34. Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis
    Fiamma Berner, Lukas Flatz · 2023 · Immunological Reviews
35. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
    Andrew Scott Brohl, Nikhil I. Khushalani, Zeynep Eroglu, Joseph Markowitz, Ram Thapa, Y. Ann Chen, Ragini Reiney Kudchadkar, Jeffrey S. Weber · 2016 · Journal for ImmunoTherapy of Cancer
36. Rapid Evolution of Thyroid Dysfunction in Patients Treated with Nivolumab
    Grenye O’Malley, Hanna J. Lee, Samir Sunil Parekh, Matthew D. Galsky, Cardinale B. Smith, Philip Adam Friedlander, Robert T. Yanagisawa, Emily J. Gallagher · 2017 · Endocrine Practice
37. Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead
    Pradnya Dinkar Patil, Mauricio Burotto, Vamsidhar Velcheti · 2018 · Expert Review of Molecular Diagnostics
38. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab
    Linda Bouhlel, J. Doyen, Emmanuel Chamorey, M. Poudenx, Marius Ilié, Jocelyn Gal, Joël Guigay, Jonathan Benzaquen, Charles‐Hugo Marquette, Jean‐Philippe Berthet et al. · 2020 · Bulletin du Cancer
39. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review
    Toshiki Kijima, Hiroshi Fukushima, Shota Kusuhara, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Noboru Numao, Yasuyuki Sakai et al. · 2020 · Clinical Genitourinary Cancer
40. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
    Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, Kartik Sehgal, Adam Ryan Miller, Kenneth L. Kehl, Deepti Venkatraman, Jacob M. Sands, Giuseppe Lamberti, Gonzalo Recondo et al. · 2020 · JTO Clinical and Research Reports
41. PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
    Geoffrey Thomas Gibney, Jacob Peter Zaemes, Shelly Shand, Neil J. Shah, David M. Swoboda, Kellie Gardner, Arash Radfar, Vesna M Petronic-Rosic, Michael J. Reilly, Waddah B. Al‐Refaie et al. · 2021 · Journal for ImmunoTherapy of Cancer
42. Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab
    Tomoki Okada, Shuzo Hamamoto, Toshiki Etani, Taku Naiki, Yasuhito Sue, Rika Banno, Kenji Yamada, Takeshi Sakakura, Takahiro Yasui · 2020 · International Cancer Conference Journal
43. ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management
    Yun Shi, Min Shen, Xuqin Zheng, Yang Chen, Ruiling Zhao, Yong Gu, Tao Yang · 2020 · The Journal of Clinical Endocrinology & Metabolism
44. Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
    Jun Sugisaka, Yukihiro Toi, Masataka Taguri, Yosuke Kawashima, Tomoiki Aiba, Sachiko Kawana, Ryohei Saito, Mari Aso, Kyoji Tsurumi, Katsuya Suzuki et al. · 2019 · JMA Journal
45. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy
    Terufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Rena Morita, Toshihiko Torigoe · 2021 · Immunological Medicine
46. Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review
    Marion Allouchery, C. Beuvon, Marie‐Christine Pérault‐Pochat, P. Roblot, Mathieu Puyade, Mickaël Martin · 2022 · Cancers
47. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer
    Koyama, Junji, Horiike, Atsushi, Yoshizawa, Takahiro, Dotsu, Yosuke, Ariyasu, Ryo, Saiki, Masafumi, Sonoda, Tomoaki, Uchibori, Ken, Nishikawa, Shingo, Kitazono, Satoru et al. · 2019 · Journal of Thoracic Disease
48. Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies
    Sarah Soussan, Guilhem Pupier, Isabelle Cremer, Pierre-Emmanuel Joubert, Catherine Sautès‐Fridman, Wolf H. Fridman, Sophie Sibéril · 2024 · Frontiers in Immunology
49. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Xin Liu, Li Su, Liyuan Ke, Hongxia Cui · 2024 · BMC Cancer
50. Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma
    Yasuhiro Nakamura, Yukiko Teramoto, Yuri Asami, Taisuke Matsuya, Jun-ichi Adachi, Ryo Nishikawa, Akifumi Yamamoto · 2017 · JAMA Dermatology
51. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient
    Georgios P. Fragulidis, Eirini V. Pantiora, Vasiliki Michalaki, Elissaios A. Kontis, Elias C. Primetis, Antonios I. Vezakis, Andreas A. Polydorou · 2017 · Journal of Oncology Pharmacy Practice
52. Immunotherapy in head and neck cancer: The great challenge of patient selection
    Martina Napolitano, Francesca Matilde Schipilliti, Lucia Trudu, Federica Bertolini · 2019 · Critical Reviews in Oncology/Hematology
53. Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study
    Taisuke Matsuya, Yasuhiro Nakamura, Shigeto Matsushita, Ryota Tanaka, Yukiko Teramoto, Yuri Asami, Jiro Uehara, Megumi Aoki, Kentaro Yamamura, Yoshiyuki Nakamura et al. · 2020 · The Journal of Dermatology
54. Fatal Autoimmune Storm After a Single Cycle of Anti-PD-1 Therapy
    Jesús Fuentes‐Antrás, Paloma Peinado, Kissy Guevara‐Hoyer, Cristina Díaz del Arco, Silvia Sánchez‐Ramón, Carlos Aguado · 2020 · Hematology/Oncology and Stem Cell Therapy
55. Association of the CD4+/CD8+ ratio with response to PD-1 inhibitor-based combination therapy and dermatological toxicities in patients with advanced gastric and esophageal cancer
    Shuangwei Xu, Qiuwei Zhu, Lixia Wu, Yaoyao Wang, Jingmiao Wang, Lina Zhu, Shanshan Zheng, Junjie Hang, Junjie Hang · 2023 · International Immunopharmacology
56. Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy
    Atsushi Narahira, Teruki Yanagi, Kyu Yong Cho, Akinobu Nakamura, Hideaki Miyoshi, Hiroo Hata, Keisuke Imafuku, Shinya Kitamura, Hiroshi Shimizu · 2016 · The Journal of Dermatology
57. Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
    Umang Swami, Varun Monga, Aaron Bossler, Yousef Zakharia, Mohammed M. Milhem · 2019 · Journal of Oncology
58. Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma
    Taku Fujimura, Takanori Hidaka, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Hisayuki Tono, Akira Tsukada, Takahiro Haga, Akira Hashimoto, Ryo Morimoto et al. · 2017 · Oncotarget
59. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score
    Yushi Ueki, Takeshi Takahashi, Hisayuki Ota, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii · 2020 · European Archives of Oto-Rhino-Laryngology
60. Higher Checkpoint Inhibitor Arthritis Disease Activity may be Associated With Cancer Progression: Results From an Observational Registry
    Karmela K Chan, Aidan Tirpack, G. Vitone, Caroline Benson, Joseph Nguyen, Nilasha Ghosh, Deanna Jannat‐Khah, Vivian P. Bykerk, Anne R. Bass · 2020 · ACR Open Rheumatology
61. Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
    Kiyoshi Minohara, Takuma Matoba, Daisuke Kawakita, Gaku Takano, Keisuke Oguri, Akihiro Murashima, Kazuhiro Nakai, Sho Iwaki, Wataru Hojo, Ayano Matsumura et al. · 2021 · Scientific Reports
62. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit
    Anisha B. Patel, Sahira Farooq, Macartney E. Welborn, Rodabe Navroze Amaria, Susan Y. Chon, Adi K. Diab, Isabella C. Glitza Oliva, Auris Huen, Shirley Q. Li, Kelly Carter Nelson et al. · 2021 · Cancer
63. Digestive Toxicities Secondary to Immune Checkpoint Inhibition Therapy – Reports of Rare Events. A Systematic Review
    Liliana Rădulescu, Dana Crișan, Cristiana Maria Grapa, Dan Rădulescu · 2021 · Journal of Gastrointestinal and Liver Diseases
64. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
    Lina María Serna-­Higuita, Teresa Maria Santos Amaral, Andrea Forschner, Ulrike Leiter, Lukas Flatz, Olivia Seeber, Ioannis Thomas, Claus Garbe, Thomas Eigentler, Peter Martus · 2021 · Cancers
65. Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
    Stavroula Α. Paschou, Michael Liontos, Evangelos Eleftherakis-Papaiakovou, Katerina Stefanaki, Christos Markellos, Konstantinos Koutsoukos, Flora Zagouri, Θεοδώρα Ψαλτοπούλου, Meletios Athanasios Dimopoulos · 2022 · Frontiers in Oncology
66. Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma
    Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura et al. · 2023 · International Journal of Urology
67. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
    Sirish Dharmapuri, Umut Özbek, Hiren Jethra, Tomi Wei Jun, Thomas Urban Marron, Anwaar Saeed, Yi‐Hsiang Huang, Mahvish Muzaffar, Matthias Pinter, Lorenz Balcar et al. · 2023 · World Journal of Gastrointestinal Oncology
68. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab
    Swami Sundaresan, Kathleen T Nguyen, Kelly Carter Nelson, Doina S. Ivan, Anisha B. Patel · 2017 · Dermatology Online Journal
69. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab)
    Shelley Ji Eun Hwang, Pablo Fernández‐Peñas · 2017 · Current problems in dermatology
70. Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy
    Marc Xipell, Iván Victoria, V. Hoffmann, Jesús Z. Villarreal, Adriana García‐Herrera, Òscar Reig, Lida Maria Rodas, Miquel Blasco, Esteban Poch, Begoña Mellado et al. · 2018 · OncoImmunology
71. Immune‐related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single‐center retrospective study in Japan
    Masaki Otsuka, Satoru Sugihara, S. Mori, Kengo Hamada, Yosuke Sasaki, Shusuke Yoshikawa, Yoshio Kiyohara · 2020 · The Journal of Dermatology
72. Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer
    Lan Huang, Li Li, Yingxu Zhou, Zhaoyang Yang, Meng Wang, Yina Gao, Yang Yang, Fang Yang, Bao Liu, Xuan Hong et al. · 2020 · Journal of Cancer
73. CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor‐specific therapies
    Maxime Barat, Sarah Guégan, Anne‐Ségolène Cottereau, Enora Guillo, Christine Caroline Hoeffel, Maximilien Barret, Sébastien Gaujoux, Anthony J.J. Dohan, Philippe A. Soyer · 2020 · Abdominal Radiology
74. Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response
    Vishnupriyadevi Parvathareddy, Umut Selamet, Aditi A. Sen, Omar Mamlouk, Juhee Song, Valda D. Page, Maen Abdelrahim, Adi K. Diab, Noha Abdel‐Wahab, Ala Abudayyeh · 2023 · Cancers
75. A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis
    Lin Zhou, Shuhui Yang, Youtao Li, Cheng Xue, Renping Wan · 2024 · Frontiers in Immunology
76. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016
    Paolo A. Ascierto, Bruno Daniele, Hans J. Hammers, Vera Hirsh, Joseph W. Kim, Lisa Francesca Licitra, Rita Nanda, Sandro Pignata · 2017 · Journal of Translational Medicine
77. Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
    Tetsuo Higashi, Hideaki Miyamoto, Ryoji Yoshida, Yoki Furuta, Katsuya Nagaoka, Hideaki Naoe, Hisaki Naito, Hideki Nakayama, Motohiko Tanaka · 2020 · Internal Medicine
78. Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis
    Kazuko Sakai, Toshiharu Sakurai, Marco Antonio De Velasco, Tomoyuki Nagai, Takaaki Chikugo, Kazuomi Ueshima, Yurie Kura, Takayuki Takahama, Hidetoshi Hayashi, Kazuhiko Nakagawa et al. · 2021 · Frontiers in Oncology
79. A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors
    Hiroki Hata, Chikako Matsumura, Yugo Chisaki, Kae Nishioka, Misaki Tokuda, Kazuyo Miyagi, Tomoki Suizu, Yoshitaka Yano · 2022 · Cancer Control
80. Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients—The European MelSkinTox study
    J.‐M. L'Orphelin, Julie Cassecuel, Lidija Kandolf Sekulović, Catherine A Harwood, PhyllisM. Tookey, Muhammad Hyder Junejo, Sarah Hogan, Célèste Lebbé, Zoé Apalla, Teresa Kränke et al. · 2023 · Journal of the European Academy of Dermatology and Venereology
81. Immune checkpoint inhibitors as a threat to reproductive function: A systematic review
    Halahati Tuerxun, Yixin Zhao, Yawen Li, Yawen Li, Shuhui Wen, Jingjing Cao, Jingjing Cao, Yuguang Zhao · 2023 · Critical Reviews in Oncology/Hematology
82. Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program
    Cornelis Bisschop, Thijs T. Wind, Christian U. Blank, Rutger H.T. Koornstra, Ellen Kapiteijn, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Mathilde Jalving, Geke A.P. Hospers · 2019 · Journal of Immunotherapy
83. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study
    Maria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, Cinzia Baldessari, Camillo Porta, Federica Iannuzzi, Umberto Basso, Sarah Scagliarini, Paolo Andrea Zucali, Luca Galli et al. · 2020 · Clinical Genitourinary Cancer
84. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
    George K.K. Lau, Bruno Sangro, Ann‐Lii Cheng, Masatoshi Kudo, Robin Kate Kelley, Won Young Tak, Antonio Gasbarrini, María Reig, Ho Yeong Lim, David Tougeron et al. · 2025 · Hepatology
85. Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives
    Daniele Marinelli, Raffaele Giusti, Marco Mazzotta, Marco Filetti, Eriseld Krasniqi, Laura Pizzuti, Lorenza Maria Landi, Federica Tomao, Federico Cappuzzo, Gennaro Ciliberto et al. · 2020 · Critical Reviews in Oncology/Hematology
86. Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance
    Tricia R. Cottrell, Jiajia Zhang, Boyang Zhang, Genevieve J. Kaunitz, Poromendro Burman, Hok Yee Chan, Franco Verde, Jody E. Hooper, Hans J. Hammers, Mohamad Ezzeddine Allaf et al. · 2021 · Journal for ImmunoTherapy of Cancer
87. Bifunctional Pdots-Based Novel ECL Nanoprobe with Qualitative and Quantitative Dual Signal Amplification Characteristics for Trace Cytokine Analysis
    Jinxia Liu, Xiaodi Liu, Huanhuan Chen, Luxia Yang, Aiting Cai, Haiwei Ji, Qi Wang, Xiaobo Zhou, Guo Li, Mingmin Wu et al. · 2022 · Analytical Chemistry
88. Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy
    Neta Bar-Hai, Guy Ben‐Betzalel, Ronen Stoff, Shirly Grynberg, Jacob Schachter, Ronnie Shapira‐Frommer, Nethanel Asher · 2023 · Cancers
89. Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study
    Heechul Nam, Jaejun Lee, Ji Won Han, Soon Kyu Lee, Hyun Yang, Hae Lim Lee, Pil Soo Sung, Hee Yeon Kim, Seok‐Hwan Kim, Myeong Jun Song et al. · 2023 · Liver Cancer
90. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4 + naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
    Magdalena Kovacsovics-Bankowski, Johanna M. Sweere, Connor P. Healy, Natalia Sigal, Li-Chun Cheng, William D. Chronister, Shane A. Evans, John Marsiglio, Berit Gibson, Umang Swami et al. · 2024 · Journal for ImmunoTherapy of Cancer
91. Inflammatory side effects of BRAF and MEK inhibitors
    Anna G. Mackin, Paula E. Pecen, Amanda L. Dinsmore, Jennifer L. Patnaik, Rene C. Gonzalez, William Allen Robinson, Alan Gary Palestine · 2019 · Melanoma Research
92. Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?
    Jordi Remón, Noemı́ Reguart, Édouard Auclin, Benjamin Besse · 2019 · Journal of Thoracic Oncology
93. Clinical burden of immune checkpoint inhibitor-induced pneumonitis
    Koji Sakamoto, Jun Fukihara, Masahiro Morise, Naozumi Hashimoto · 2020 · Respiratory Investigation
94. C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting
    Justine Lauwyck, Aline Beckwée, Arno Santens, Julia Katharina Schwarze, Gil Awada, Valérie Vandersleyen, Sandrine Aspeslagh, Bart Neyns · 2021 · Melanoma Research
95. Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients
    Taketo Kawai, Yusuke Sato, Katsuhiro Makino, Yuta Yamada, Akira Nomiya, Masaki Nakamura, Daisuke Yamada, Motofumi Suzuki, Yasuhiko Igawa, Haruki Kume · 2019 · European Journal of Cancer
96. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy
    T. Finazzi, T. Rordorf, K. Ikenberg, G. F. Huber, M. Guckenberger, H. I. Garcia Schueler · 2018 · BMC Cancer
97. Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)
    Naoya Yamazaki, Tatsuya Takenouchi, Yasuhiro Nakamura, Akira Takahashi, Kenjiro Namikawa, Shigehisa Kitano, Tomonobu Fujita, Kazumi Kubota, Takeharu Yamanaka, Yutaka Kawakami · 2021 · Japanese Journal of Clinical Oncology
98. Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases
    J.‐M. L'Orphelin, Émilie Varey, Amir Khammari, Brigitte Dréno, A. Dompmartin · 2021 · Cancers
99. Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival
    Hannah Smith, Robert S. Easterling, Jianing Ma, Meghana Moodabagil, Alexa Simon Meara, Dwight Hall Owen, Elliott D. Crouser, Arindam Singha, Kevin Ho · 2024 · Respiratory Medicine
100. Genome-wide association analyses of autoimmune hypothyroidism reveal autoimmune and thyroid-specific contributions and an inverse relationship with cancer risk
     Mary Pat Reeve, Masahiro Kanai, Daniel B. Graham, Juha M Karjalainen, Shuang Luo, Nikita Kolosov, Cameron Adams, Jarmo Ritari, Konrad J. Karczewski, Tuomo Kiiskinen et al. · 2026 · Nature Genetics